Genmab A (GMAB) Operating Margin (2018 - 2026)
Genmab A's (GMAB) quarterly Operating Margin came in at 32.47% in Q2 2026, down 95.0% on a YoY basis from 649.35% in Q2 2025, and up 61.62% quarter-over-quarter from 20.09% in Q1 2026.
Powered by 
Analysis
Genmab A (GMAB) Operating Margin (2018 - 2026) Analysis & Trends
Genmab A (GMAB) has reported Operating Margin for 9 consecutive years, with 32.47% the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Operating Margin fell 95.0% year-over-year to 32.47%; the trailing twelve-month figure through Jun 2026 stood at 33.21% (up 373.0% YoY), and the FY2025 full-year result was 28.63%, down 251.0% from the prior year.
- Operating Margin grew to 32.47% in Q2 2026 per GMAB's latest filing, from 20.09% in the prior quarter.
- Across five years, Operating Margin topped out at 39.44% in Q2 2022 and bottomed at 19.24% in Q1 2024.
- Historically, Operating Margin has averaged 30.11% across 5 years, with a median of 30.61% in 2023.
- The sharpest annual moves came in 2025 and 2026: Operating Margin soared 794 bps in 2025, then slumped 620 bps in 2026.
- Over 5 years, Operating Margin stood at 39.44% in 2022, then declined by 22 bps to 30.61% in 2023, then retreated by 2 bps to 30.12% in 2024, then advanced by 26 bps to 37.83% in 2025, then retreated by 14 bps to 32.47% in 2026.
- According to Business Quant data, Operating Margin over the past three periods registered 32.47%, 20.09%, and 37.83% for Q2 2026, Q1 2026, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 208.48 Bn | 194.49 Bn | 7.24 Bn | 34.95% |
| 2 | Gilead Sciences | 186.29 Bn | 183.02 Bn | 6.22 Bn | -133.21% |
| 3 | Vertex Pharmaceuticals | 128.79 Bn | 120.93 Bn | 2.84 Bn | 37.40% |
| 4 | Regeneron Pharmaceuticals | 80.66 Bn | 72.67 Bn | 3.93 Bn | 30.15% |
| 5 | Moderna | 61.46 Bn | 56.32 Bn | 52.00 Mn | -562.07% |
| 6 | Argenx Se | 61.28 Bn | 56.10 Bn | 1.37 Bn | 32.54% |
| 7 | Alnylam Pharmaceuticals | 32.04 Bn | 28.73 Bn | 992.69 Mn | 17.93% |
| 8 | Biogen | 31.84 Bn | 30.56 Bn | 1.96 Bn | -23.56% |
| 9 | Roivant Sciences | 28.74 Bn | 29.43 Bn | 1.16 Mn | -25,380.93% |
| 10 | Genmab A | 2.23 Bn | 728.64 Mn | 1.07 Bn | 32.47% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 32.47% |
| Mar 31, 2026 | 20.09% |
| Sep 30, 2025 | 37.83% |
| Jun 30, 2025 | 33.41% |
| Mar 31, 2025 | 26.29% |
| Sep 30, 2024 | 30.12% |
| Jun 30, 2024 | 25.47% |
| Mar 31, 2024 | 19.24% |
| Dec 31, 2023 | 30.61% |
| Sep 30, 2023 | 36.19% |
| Jun 30, 2022 | 39.44% |
| Dec 31, 2021 | 39.91% |
| Sep 30, 2021 | 38.53% |
| Jun 30, 2021 | 39.91% |
| Dec 31, 2020 | 82.50% |
| Sep 30, 2020 | 49.77% |
| Dec 31, 2019 | 33.75% |
| Sep 30, 2019 | 33.73% |
| Jun 30, 2019 | 17.70% |
| Dec 31, 2018 | 33.44% |